Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Burosumab dose adjustment study in children with FGF23-related hypophosphatemic rickets
jRCT1031260418Recruiting
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of burosumab in FGF23-dependent hypophosphatemia (3 arms). Primary endpoint: Change in height SDS at 1 year. Started Aug 2026; status: recruiting.
02
Drugs
burosumab
03
Conditions
FGF23-dependent hypophosphatemia
Beyond the preview
Go deeper on jRCT1031260418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031260418.